Nasdaq
华尔街日报Earnings Not Telling The Story For Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)
With a price-to-earnings (or "P/E") ratio of 22.1x Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) may be sending bearish signals at the moment, given that almost half of all companies in Saudi Arabia have P/E ratios under 17x and even P/E's lower than 12x are not unusual. However, the P/E might be high for a reason and it requires further investigation to determine if it's justified.
With earnings growth that's superior to most other companies of late, Jamjoom Pharmaceuticals Factory has been doing relatively well. The P/E is probably high because investors think this strong earnings performance will continue. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.
Check out our latest analysis for Jamjoom Pharmaceuticals Factory
How Is Jamjoom Pharmaceuticals Factory's Growth Trending?
Jamjoom Pharmaceuticals Factory's P/E ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the market.
If we review the last year of earnings growth, the company posted a terrific increase of 28%. The latest three year period has also seen an excellent 77% overall rise in EPS, aided by its short-term performance. So we can start by confirming that the company has done a great job of growing earnings over that time.
Shifting to the future, estimates from the four analysts covering the company suggest earnings should grow by 13% per year over the next three years. With the market predicted to deliver 12% growth per year, the company is positioned for a comparable earnings result.
In light of this, it's curious that Jamjoom Pharmaceuticals Factory's P/E sits above the majority of other companies. It seems most investors are ignoring the fairly average growth expectations and are willing to pay up for exposure to the stock. Although, additional gains will be difficult to achieve as this level of earnings growth is likely to weigh down the share price eventually.
The Final Word
We'd say the price-to-earnings ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.
We've established that Jamjoom Pharmaceuticals Factory currently trades on a higher than expected P/E since its forecast growth is only in line with the wider market. When we see an average earnings outlook with market-like growth, we suspect the share price is at risk of declining, sending the high P/E lower. Unless these conditions improve, it's challenging to accept these prices as being reasonable.
A lot of potential risks can sit within a company's balance sheet. You can assess many of the main risks through our free balance sheet analysis for Jamjoom Pharmaceuticals Factory with six simple checks.
Of course, you might also be able to find a better stock than Jamjoom Pharmaceuticals Factory. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.